Clinical - OnKure, Inc.

Candidate Program Cand Prog	Indication Target Class Ind Target	Discovery Discov	Phase 1 Ph 1	Phase 2 Ph 2	Pivotal Trial Pivotal	Partner Ptr
OKI-179
	NRAS Melanoma Combo w/Binimetinib
OKI-179	NRAS Melanoma Combo w/Binimetinib
Class-1 HDAC inhibition has been shown to dramatically enhance the efficacy of MEK inhibitors in Ras pathway driven melanomas by coordinately suppressing two DNA repair pathways. A potential clinical biomarker that predicts responsiveness has also been identified.

Discovery

Candidate Program Cand Prog	Indication Target Class Ind Target	Discovery Discov	Phase 1 Ph 1	Phase 2 Ph 2	Pivotal Trial Pivotal	Partner Ptr
ONK-001
	Kinase Target
ONK-001	Kinase Target
ONK-002
	Kinase Target
ONK-002	Kinase Target
ONK-003
	Kinase Target
ONK-003	Kinase Target
ONK-004
	Kinase Target
ONK-004	Kinase Target
ONK-005
	Non-Kinase Target
ONK-005	Non-Kinase Target
ONK-006
	Non-Kinase Target
ONK-006	Non-Kinase Target